Retraction Note: Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice

Pan Zhang, Zelin Lai, Huifen Chen, Min Zhang, An Wang, Tao Jia, Wenqin Sun, Ximin Zhu, Xiaofeng Chen, Zheng Zhao, Jun ZhangJournal of Experimental & Clinical Cancer Research 2022 · DOI · OpenAlex

Abstract

In 2022, the Journal of Experimental & Clinical Cancer Research issued a formal retraction for a 2017 study titled "Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice." While the original research presented a promising mechanism for overcoming chemoresistance in colon cancer, the retraction was necessitated by significant concerns regarding animal welfare and the lack of verifiable ethical oversight. This mini-paper reviews the context of the retraction and its implications for the oncology research community.

Introduction: The Promise of Curcumin and 5-FU

Colorectal cancer remains a leading cause of cancer-related mortality, often due to the development of resistance to standard chemotherapeutic agents like 5-fluorouracil (5-FU). The original 2017 study aimed to address this clinical challenge by investigating the synergistic potential of curcumin, a polyphenol derived from turmeric.

The authors hypothesized that curcumin could sensitize colon cancer cells to 5-FU by modulating the AMPK/ULK1 signaling pathway. This pathway is a critical regulator of autophagy—a process where cells degrade their own components to survive under stress. In the context of cancer, autophagy can act as a survival mechanism against chemotherapy. By inhibiting this "self-eating" process and suppressing AKT activity, the study claimed that the combination therapy could effectively trigger apoptosis (programmed cell death) and inhibit tumor growth in mouse models.

The Basis for Retraction: Ethical and Welfare Concerns

Despite the potential therapeutic insights, the study was retracted five years after publication following an editorial audit. The primary issues identified by the Editor-in-Chief centered on the in vivo (animal) component of the research.

1. Humane Endpoints and Tumor Volume

In oncology research involving xenograft models (where human cancer cells are grown in mice), strict ethical guidelines govern the maximum allowable size of a tumor. These are known as "humane endpoints"—predefined criteria that dictate when an animal must be euthanized to prevent unnecessary pain and distress. The journal raised concerns that the tumor volumes reported in the study may have exceeded the limits permitted by institutional and international ethical standards.

2. Lack of Ethical Verification

A cornerstone of modern scientific publishing is the verification of ethical approval from an Institutional Animal Care and Use Committee (IACUC) or an equivalent body. During the investigation, the journal was unable to obtain sufficient evidence that the experiments had been conducted under the appropriate ethical approvals or that the humane endpoints were strictly monitored and enforced.

The Role of Author Accountability

A notable aspect of this retraction is the communication breakdown between the publisher and the research team. According to the retraction note, none of the authors responded to any correspondence from the journal regarding the investigation or the decision to retract.

In the scientific community, the failure of authors to engage with inquiries regarding data integrity or ethical compliance is often interpreted as a significant indicator of unreliability. This silence effectively prevented any clarification that might have saved the paper, such as providing original lab notebooks or signed ethics certificates.

Implications for the Scientific Record

The retraction of this study serves as a critical reminder that the scientific process is self-correcting and extends far beyond the initial date of publication.

  • Nullification of Findings: The claims regarding the AMPK/ULK1 pathway and the synergistic effects of curcumin and 5-FU are no longer considered part of the validated scientific literature. Researchers must now treat these findings with extreme caution, as the underlying data cannot be verified.
  • Emphasis on Animal Welfare: The action taken by Springer Nature underscores a growing commitment among major publishers to prioritize animal welfare. Even if the molecular findings of a study appear sound, ethical breaches in the treatment of animal subjects are sufficient grounds for removal from the record.
  • Post-Publication Peer Review: The five-year gap between publication and retraction highlights the importance of ongoing scrutiny by the global research community.

Conclusion

The retraction of the curcumin/5-FU synergy study highlights the inextricable link between ethical conduct and scientific validity. While the search for chemosensitizers in colon cancer continues, this case emphasizes that the "how" of research is just as important as the "what." Future studies in this area must ensure rigorous adherence to animal welfare protocols and maintain transparent, accessible records of ethical approvals to safeguard the integrity of their findings.

Summary updated

Abstract

This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-022-02409-y.
BibTeX
@article{zhang2022retraction,
  author = {Pan Zhang and Zelin Lai and Huifen Chen and Min Zhang and An Wang and Tao Jia and Wenqin Sun and Ximin Zhu and Xiaofeng Chen and Zheng Zhao and Jun Zhang},
  title = {{Retraction Note: Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2022},
  doi = {10.1186/s13046-022-02409-y},
}
Figure